Skip to content
Lower risk Drug recall · FDA · Published November 17, 2023

InvaGen Vigabatrin Oral Solution Recall: Leaking Powder Hazard

InvaGen Pharmaceuticals recalls Vigabatrin oral solution due to risk of powder leaking from pouches. This medication is prescription-only and may cause ineffective treatment if powder leaks.

🇺🇸 FDA recall #D-0220-2024DrugInvaGen ›
Take action

Contact the company

Recalling firmInvaGen Pharmaceuticals, Inc.550 S Research Pl · Central Islip, NY 11722-4415
✎ GovInfoNow plain-language explainer

InvaGen Pharmaceuticals is recalling Vigabatrin oral solution (500 mg per packet) because the pouches may leak powder. This could lead to ineffective treatment if the medication is not properly administered. Read more at govinfonow.com/recall/32944-invagen-vigabatrin-oral-solution-recall-leaking-powder-hazard.

Source Summary by GovInfoNow · govinfonow.com/recall/32944-invagen-vigabatrin-oral-solution-recall-leaking-powder-hazard · Updated September 23, 2026 · FDA enforcement record: FDA #D-0220-2024

Cite this page

“InvaGen Vigabatrin Oral Solution Recall: Leaking Powder Hazard.” GovInfoNow, updated September 23, 2026. https://govinfonow.com/recall/32944-invagen-vigabatrin-oral-solution-recall-leaking-powder-hazard. Based on FDA recall #D-0220-2024 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0220-2024%22&limit=1).

InvaGen Pharmaceuticals, Inc. voluntarily recalled Vigabatrin for Oral Solution on Nov. 17, 2023, after the FDA announced the Class I recall due to defective containers that may allow powder to leak. The Food and Drug Administration issued the recall notice under agency number D-0220-2024.

How to tell if you have it

  • Brand: InvaGen
  • Product: Vigabatrin for Oral Solution, USP 500 mg per packet, 50 packets per box
  • NDC: 69097-964-53
  • Lot #: NB301030
  • Exp. Date: 03/31/2025
  • Quantity: 1240 boxes

The hazard

The recall addresses defective containers in which the powder may leak out of the pouch. The FDA classified this as a Class I recall, indicating a high risk of serious adverse health consequences or death.

Context

GovInfoNow's records show InvaGen Pharmaceuticals, Inc. has had 7 other recalls on record since March 5, 2018. Other recent recalls of similar products include Mallinckrodt Acthar Gel 5mL Vial Recall (Aug. 6, 2026), B Braun Dextrose Injection Recall (April 2, 2026), and Radnostix Sodium Iodide Solution Recall (Jan. 26, 2026).

How to tell if you have this one

Check for Vigabatrin oral solution packets labeled '500 mg per packet, 50 packets per box' manufactured by InvaGen Pharmaceuticals. The product was made in Hauppauge, NY with lot number NB301030 and expires March 31, 2025.

  • Brand
    InvaGen
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check Medication

    Verify the product label matches the description: Vigabatrin oral solution, 500 mg per packet, 50 packets per box, manufactured by InvaGen Pharmaceuticals.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “Nationwide within the United States” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA published this recall 2 months after the firm started it.

1. Firm started the recall: Nov 17, 202312. FDA classified it Class I: Jan 8, 202423. Published in FDA’s Enforcement Report: Jan 17, 2024320232024
  1. Firm started the recall
  2. FDA classified it Class I
  3. Published in FDA’s Enforcement Report

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0220-2024 (November 17, 2023) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0220-2024 to see it in context.
  • Plain-language summary written by qwen3:4b on September 23, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA